Biotech Startups

Liposphere is a biomedical startup spun out of Israel's Weizmann Institute that develops liposome-based biolubricant materials for orthopaedic conditions. Its technology targets joint pain and mobility in patients with osteoarthritis and can coat both cartilage and artificial medical surfaces such as implants and catheters.

1 investor

Lipock develops nanoencapsulation technology that stabilizes natural bioactives — such as rosemary and thyme extracts — so they remain potent, cost-competitive, and can be integrated into existing industrial production lines. It supplies natural preservatives and antioxidants for food, beverage, nutraceutical, and cosmetics manufacturers seeking clean-label alternatives to synthetic preservatives like BHT and BHA.

1 investor

Lipogems International Spa is an Italian biotech company in regenerative medicine that developed the Lipogems system for processing adipose (fat) tissue used in minimally invasive treatments for conditions such as osteoarthritis, inflammation, soft-tissue injuries, and wounds. Its clinically tested products are used by doctors, surgeons, and researchers worldwide.

1 investor

Liposeuticals develops proprietary formulations of sterile injectable drugs for hospital use, focusing on anesthesiology, oncology, and infectious disease treatments. The company's sugar-lipid polymer technology platform reformulates water-insoluble compounds to improve stability, shelf life, manufacturability, and patient safety compared to existing emulsion-based approaches.

1 investor

Liquet Medical develops localized drug delivery technology for treating vascular disease. The company focuses on medical devices aimed at improving patient outcomes in vascular care.

1 investor

Liquidia Technologies is a biopharmaceutical company that develops and commercializes drugs for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, including YUTREPIA, an inhaled dry-powder treprostinil formulation, and treprostinil injection through a profit-sharing arrangement with Sandoz, along with pipeline candidates based on its PRINT particle-engineering platform.

1 investor

Lisata develops drug delivery platform technology and therapies for solid tumors, enabling targeted anti-cancer drug delivery and immune system activation against cancer.

1 investor

LisenID develops a molecular diagnostics test and platform that uses Loss of Imprinting (LOI) epigenetic biomarkers combined with AI to detect and predict cancer from routine tumor biopsy samples across multiple cancer types. It targets clinicians and patients facing ambiguous biopsy results, working in the cancer diagnostics field.

1 investor

List Labs provides contract manufacturing and development services for biopharmaceutical products, including live biotherapeutics, toxin therapeutics, and monoclonal antibodies for clinical trials and commercial production. The company serves biotech developers and pharmaceutical companies requiring cGMP manufacturing and process development expertise.

1 investor

Little Green Pharma develops and manufactures natural and alternative health products from facilities in Denmark and Australia, and conducts clinical research into alternative therapies. It serves the European and Australian natural health sector.

1 investor

Liven develops animal-free protein ingredients using synthetic biology and precision fermentation, growing engineered microorganisms on food-industry side streams and lost food. The ingredients address functional challenges (gelling, emulsification, texture) in plant-based food formulations for the food industry.

1 investor

LiVeritas Biosciences provides AI-powered molecular testing and analytical workflows that produce validated, submission-ready outputs to support drug developers with regulatory filings such as INDs. Its SaaS platform LiLii centralizes project management, CRM, document control, and analytics for biopharma clients.

1 investor

LiveSpo develops spore probiotic products and technologies designed to promote gut health and reduce reliance on antibiotics. The company serves consumers and healthcare applications through various probiotic formulations based on proprietary sporulation and activation technologies.

1 investor

Livestock Labs sources and engineers stable, controllable cell lines that serve as the starting material for next-generation animal products such as cultivated meat, leather, and cosmetics. It supplies engineered cell lines and documentation to cultivated meat companies, media and ingredient partners, bioprocess groups, and researchers.

1 investor

LivFul develops and distributes safe medicines and health solutions aimed at diseases affecting the global south, including neglected tropical diseases (NTDs). The company focuses on health access and clinical validation for developing countries and emerging markets.

1 investor

BioLizard provides analytics and AI solutions to convert complex biomedical data into actionable insights for pharmaceutical and biotech companies across discovery and clinical development phases.

1 investor

Lmito Therapeutics is a drug discovery company focused on mitochondrial and cell metabolism, targeting areas such as immunology, neuroimmunology, and immuno-oncology. It operates using a fully integrated pharmaceutical network (FIPNet) business model.

1 investor

A biotechnology company that develops creative biotech solutions to improve human health and well-being.

1 investor

Lingtaike Biotech develops nucleic acid drugs based on lncRNA, using its proprietary lncRNA-mediated targeting chimera technology (lncTAC) combined with the UNAST platform to target traditionally undruggable disease targets. The company focuses on drug discovery for unmet clinical needs in the lncRNA field.

1 investor

1 investor

Lomond Therapeutics is a small molecule oncology drug discovery company developing differentiated therapies that target biological pathways with resistant mutations and escape mechanisms in hematologic malignancies. It focuses on pan-variant therapies aimed at overcoming resistance in current cancer treatments.

1 investor

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule medicines targeting G protein-coupled receptors for neurological diseases, with an initial focus on rare conditions. Its lead candidate, bexicaserin (LP352), is an oral 5-HT2C receptor superagonist in development for seizures associated with developmental and epileptic encephalopathies; the company is now a subsidiary of Lundbeck.

1 investor

The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause. The foundation is raising capital to simultaneously advance measurement technologies, biological understanding, and early-stage interventions targeting reproductive aging.

1 investor

The Longevity Biotechnology Association is a global non-profit organization that convenes longevity biotech companies, pharmaceuticals, researchers, and investors to establish industry standards and advance the translation of geroscience into therapeutic interventions that prevent age-related diseases and extend health span.

1 investor